Xilio Therapeutics, INC Schedule 13G passive stakes

StemPoint Capital LP, along with affiliated entities, has reported beneficial ownership of 628,866 shares, representing 9.5% of Xilio Therapeutics' common stock, primarily through warrants.

OrbiMed Advisors LLC and OrbiMed Capital GP X LLC have filed a Schedule 13G reporting a combined beneficial ownership of 9.99% in Xilio Therapeutics, Inc.

Bain Capital Life Sciences entities report a 9.99% beneficial ownership stake in Xilio Therapeutics, Inc. via pre-funded warrants.

Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, reporting beneficial ownership of 9.9% of Xilio Therapeutics, Inc. common stock, primarily through exercisable warrants.

StemPoint Capital LP, along with its general partner and Michelle Ross, has disclosed an 8.4% beneficial ownership stake in Xilio Therapeutics, Inc., comprising common stock and warrants.

Frazier Life Sciences Public Fund and affiliated entities reported a combined beneficial ownership of 6.7% in Xilio Therapeutics, Inc. common stock as of December 31, 2025.

Gilead Sciences, Inc. has increased its beneficial ownership in Xilio Therapeutics, Inc. to 19.9% through a series of share issuances and pre-funded warrants.

Coastlands Capital LP and its affiliates have reported a 9.99% beneficial ownership stake in Xilio Therapeutics, Inc., totaling 5,346,069 shares.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, reported a 9.9% beneficial ownership stake in Xilio Therapeutics, Inc., primarily through warrants.

StemPoint Capital LP, along with its affiliates, has reported a 7.2% beneficial ownership stake in Xilio Therapeutics, Inc., primarily through warrants.

Gilead Sciences, Inc. has disclosed a significant beneficial ownership stake of 19.9% in Xilio Therapeutics, Inc., holding over 10.6 million shares.

Frazier Life Sciences and its affiliated funds have filed an amended Schedule 13G, clarifying their beneficial ownership in Xilio Therapeutics, Inc., primarily through pre-funded warrants.

Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen have jointly disclosed a 7.2% passive beneficial ownership stake in Xilio Therapeutics, Inc., primarily through warrants.

Frazier Life Sciences and its affiliated funds, along with key managing members, have reported beneficial ownership of up to 9.9% of Xilio Therapeutics, Inc. common stock through exercisable pre-funded warrants.

Rock Springs Capital Management LP and its affiliated entities have filed an amended Schedule 13G, indicating a complete divestment of their beneficial ownership in Xilio Therapeutics, Inc., now holding 0% of the common stock.

AbbVie Inc. has disclosed a significant 9.0% beneficial ownership stake in Xilio Therapeutics, Inc., acquiring over 4.3 million shares of common stock.